Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Cullell-Young
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Related publications
First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors
Molecular Cancer Therapeutics
Cancer Research
Oncology
Erratum To: First-In-Human Phase I Study of SOR-C13, a TRPV6 Calcium Channel Inhibitor, in Patients With Advanced Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
Phase I Study of Single-Agent Ribociclib in Japanese Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Study of NLG919 for Adult Patients With Recurrent Advanced Solid Tumors
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A Phase I Study of BMS-690514 in Japanese Patients With Advanced or Metastatic Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
